Peringkat dalam Saham
#16324
Valbiotis SA engages in the research and development of health nutrition... Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
Kapitalisasi Pasar
$22.26M
Perubahan (1 tahun)
-14.35%
Perdagangan Valbiotis SA (ALVAL)
Harga ALVAL dengan kapitalisasi pasar B
Kapitalisasi pasar dari Valbiotis SA(ALVAL)
Kapitalisasi Pasar: $22.26M
Per July 2026, Valbiotis SA memiliki kapitalisasi pasar sebesar $22.26M. Ini menjadikan Valbiotis SA sebagai perusahaan 16324th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Valbiotis SA dari 2017 hingga 2026
ALVAL dibandingkan dengan 5 teratas stocks paling populer
| Harga ALVAL |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.130T
|
+23,040,965.29%
|
|
|
|
|
$4.624T
|
+20,770,337.38%
|
|
|
|
|
$4.348T
|
+19,529,651.60%
|
|
|
|
|
$2.859T
|
+12,842,806.60%
|
|
|
|
|
$2.662T
|
+11,957,317.43%
|
